After a year of rocky financials and trial readouts, Quince Therapeutics is charting a new path forward and relaunching with ...
Revolution Medicines’ stock slid 6.3% Thursday after newly released FDA review documents sparked investor unease around ...
With a Friday go-ahead from the FDA, another key piece of Teva’s innovation revamp strategy has fallen into place, further ...
Novartis bought an mRNA-coded autoimmune T-cell engager candidate for up to $7.8 billion, as Shionogi offered $2 billion to ...
Promotional interactions between clinicians and pharmaceutical companies are probably associated with harmful outcomes, ...
With the FDA approval of Zenbexus this summer, Bristol Myers Squibb checked off two notable ‘firsts,’ scoring the inaugural ...
Generic drugmaker Viatris is beefing up its pain medicine portfolio with a $1.65 billion deal to buy Pacira BioSciences and ...
As the Trump administration advances plans to bring its “most favored nation” drug pricing model to Medicare Part B, the ...
Just shy of two months after teeing up its FcRn blocker Vyvgart Hytrulo for entry into another potential immunology niche, ...
Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...
After facing a setback in Germany late last year, Merck & Co.’s European marketing plans for its below-the-skin Keytruda SC are growing more complicated. | After facing a setback in Germany late last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results